Das IOZK ist ein translationales Zentrum und entwickelt immunonkologische Verfahren auf der Basis neuer wissenschaftlicher Erkenntnisse.
Diese werden für die Patienten individuell in der bestmöglichen Weise kombiniert. Deshalb werden im IOZK keine randomisierten, klinischen Studien durchgeführt. Diese erfordern nämlich das gleiche Behandlungsprotokoll für alle Patienten in der Experimentalgruppe und eine Vergleichsgruppe, die keine Behandlung erhält. In der Wissenschaft werden neue Erkenntnismethoden entwickelt und diskutiert, die besser geeignet sind, die Wirksamkeit einer stark individualisierten Therapie zu untersuchen. Es ist uns ein großes Anliegen, zum wissenschaftlichen Fortschritt und der Entwicklung der modernen Immuntherapie gegen Tumorkrankheiten beizutragen.
Hier stellen wir wissenschaftliche Arbeiten zur Verfügung, die von Mitarbeitern des IOZK veröffentlicht wurden.
Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
Myeloid-derived suppressor cells in glioma
Dendritic cell-based immunotherapy in ovarian cancer
Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity
Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours
Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination